338 related articles for article (PubMed ID: 19596534)
1. Use of a quality-by-design approach to justify removal of the HPLC weight % assay from routine API stability testing protocols.
Skrdla PJ; Wang T; Antonucci V; Dowling T; Ge Z; Ellison D; Curran J; Mohan G; Wyvratt J
J Pharm Biomed Anal; 2009 Dec; 50(5):794-6. PubMed ID: 19596534
[TBL] [Abstract][Full Text] [Related]
2. Is HPLC assay for drug substance a useful quality control attribute?
Hofer JD; Olsen BA; Rickard EC
J Pharm Biomed Anal; 2007 Aug; 44(4):906-13. PubMed ID: 17540527
[TBL] [Abstract][Full Text] [Related]
3. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
Lalitha Devi M; Chandrasekhar KB
J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
[TBL] [Abstract][Full Text] [Related]
4. Improving method capability of a drug substance HPLC assay.
Dejaegher B; Jimidar M; De Smet M; Cockaerts P; Smeyers-Verbeke J; Vander Heyden Y
J Pharm Biomed Anal; 2006 Sep; 42(2):155-70. PubMed ID: 16621413
[TBL] [Abstract][Full Text] [Related]
5. Relationship between HPLC precision and number of significant figures when reporting impurities and when setting specifications.
Agut C; Segalini A; Bauer M; Boccardi G
J Pharm Biomed Anal; 2006 May; 41(2):442-8. PubMed ID: 16472956
[TBL] [Abstract][Full Text] [Related]
6. A stability-indicating reversed-phase high performance liquid chromatography method for simultaneous assay of two corticosteroids and estimation of their related compounds in a pharmaceutical injectable formulation.
Lu J; Wei Y; Rustum AM
J Chromatogr A; 2010 Oct; 1217(44):6932-41. PubMed ID: 20855075
[TBL] [Abstract][Full Text] [Related]
7. A validated stability indicating ion-pair RP-LC method for zoledronic acid.
Rao BM; Srinivasu MK; Rani ChP; kumar SS; Kumar PR; Chandrasekhar KB; Veerender M
J Pharm Biomed Anal; 2005 Sep; 39(3-4):781-90. PubMed ID: 15922532
[TBL] [Abstract][Full Text] [Related]
8. Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts.
Skibsted ET; Boelens HF; Westerhuis JA; Witte DT; Smilde AK
J Pharm Biomed Anal; 2006 Apr; 41(1):26-35. PubMed ID: 16289623
[TBL] [Abstract][Full Text] [Related]
9. Identification, synthesis and quantification of process-related impurities in auraptene.
Li YG; Chen HF; Tu MZ; Zhang PZ; Wang XY; Yuan JB; Yang WL
J Pharm Biomed Anal; 2011 Sep; 56(2):191-9. PubMed ID: 21705169
[TBL] [Abstract][Full Text] [Related]
10. Determination of inorganic pharmaceutical counterions using hydrophilic interaction chromatography coupled with a Corona CAD detector.
Huang Z; Richards MA; Zha Y; Francis R; Lozano R; Ruan J
J Pharm Biomed Anal; 2009 Dec; 50(5):809-14. PubMed ID: 19616396
[TBL] [Abstract][Full Text] [Related]
11. Use of high resolution LC-MSn analysis in conjunction with mechanism-based stress studies: identification of asarinin, an impurity from sesame oil in an animal health product.
Wang X; Peng Y; Li M; Rustum AM
J Pharm Biomed Anal; 2009 Dec; 50(5):1015-21. PubMed ID: 19631486
[TBL] [Abstract][Full Text] [Related]
12. LC-MS characterization of trace impurities contained in calcium folinate.
Francese G; Corana F; Meneghetti O; Marazza F
J Pharm Biomed Anal; 2005 Sep; 39(3-4):757-63. PubMed ID: 15927438
[TBL] [Abstract][Full Text] [Related]
13. Impurity profile tracking for active pharmaceutical ingredients: case reports.
Zhou L; Mao B; Reamer R; Novak T; Ge Z
J Pharm Biomed Anal; 2007 Jun; 44(2):421-9. PubMed ID: 17142001
[TBL] [Abstract][Full Text] [Related]
14. A stability-indicating HPLC method for the determination of glucosamine in pharmaceutical formulations.
Shao Y; Alluri R; Mummert M; Koetter U; Lech S
J Pharm Biomed Anal; 2004 May; 35(3):625-31. PubMed ID: 15137989
[TBL] [Abstract][Full Text] [Related]
15. A stability-indicating HPLC assay with diode array detection for the determination of a benzylpenicillin prodrug in aqueous solutions.
Jain R; Wu Z; Tucker IG
J Pharm Biomed Anal; 2009 Dec; 50(5):841-6. PubMed ID: 19640667
[TBL] [Abstract][Full Text] [Related]
16. A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
Gavin PF; Olsen BA; Wirth DD; Lorenz KT
J Pharm Biomed Anal; 2006 Jun; 41(4):1251-9. PubMed ID: 16621411
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
Nageswara Rao R; Narasa Raju A; Narsimha R
J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
[TBL] [Abstract][Full Text] [Related]
18. The sacred cow: the questionable role of assay methods in characterising the quality of bulk pharmaceuticals.
Görög S
J Pharm Biomed Anal; 2005 Jan; 36(5):931-7. PubMed ID: 15620516
[TBL] [Abstract][Full Text] [Related]
19. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.
Chen Y; Brill GM; Benz NJ; Leanna MR; Dhaon MK; Rasmussen M; Zhou CC; Bruzek JA; Bellettini JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):106-17. PubMed ID: 17826364
[TBL] [Abstract][Full Text] [Related]
20. Hyphenated HPLC-NMR and its applications in drug discovery.
Peng SX
Biomed Chromatogr; 2000 Oct; 14(6):430-41. PubMed ID: 11002280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
